Iovance Biotherapeutics Inc. (IOVA)

IOVA (NASDAQ:Biotechnology) EQUITY
$15.95
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | IOVA Avg Daily Volume: 967,900
Last Update: 08/14/18 - 4:00 PM EDT
Volume: 0
YTD Performance: 99.38%
Open: $0.00
Previous Close: $15.95
52 Week Range: $4.45 - $19.90
Oustanding Shares: 95,592,000
Market Cap: 1,433,880,005
6-Month Chart
TheStreet Ratings Grade for IOVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 7
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.00 1.00 1.00 1.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -11.11
Price Earnings Comparisons:
IOVA Sector Avg. S&P 500
-11.11 0.00 20.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.33% 215.84% 123.08%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.00 0.00 0.00
Net Income -23.78 6.70 0.00
EPS -23.78 1.90 0.00
Earnings for IOVA:
EBITDA -0.09B
Revenue 0.00B
Average Earnings Estimates
Qtr (09/18) Qtr (12/18) FY (12/18) FY (12/19)
Average Estimate $-0.34 $-0.34 $-1.32 $-1.43
Number of Analysts 6 5 7 7
High Estimate $-0.30 $-0.30 $-1.24 $-1.24
Low Estimate $-0.36 $-0.37 $-1.39 $-1.62
Prior Year $-0.35 $-0.36 $-1.41 $-1.32
Growth Rate (Year over Year) 4.29% 5.00% 6.48% -8.34%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
As interest rate fears ease slightly, indexes rebound.
While I'm waiting for some index excitement I'm focused on trades in individual stocks.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
It's hard to believe the bounce will continue to run in V-shaped fashion.
If we have a little consolidating action here the buyers will start pushing again.
In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.
While painful to longs, the market will be better for it.
It would be a longer-term positive if the overbought conditions are alleviated.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.

Columnist Conversations

View Chart »  View in New Window » BA chart I'm STALKING this one for a buy trigger........
View Chart »  View in New Window »   WEEKLY
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

COLUMNIST TWEETS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.